Pramlintide in the treatment of type 1 and type 2 diabetes mellitus

Use of pramlintide in addition to insulin1026 in patients with type 1 and type 2 diabetes was associated with modest reductions in HbA1c. The primary adverse effects of pramlintide therapy were nausea and hypoglycemia.